Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke

Atherosclerosis

Volumn 208, Issue 2, 2010, Pages 518-523

  Schulze, Friedrich ^a   Carter, Angela M ^b   Schwedhelm, Edzard ^a   Ajjan, Ramzi ^b   Maas, Renke ^a,c   von Holten, Rouven Alexander ^a   Atzler, Dorothee ^a   Grant, Peter J ^b   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Atrial fibrillation; Haemostasis; Nitric oxide; Prognosis; Renal function; Risk marker

Indexed keywords

ALBUMIN; ARGININE; BETA THROMBOGLOBULIN; C REACTIVE PROTEIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL VASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

EID: 74749108725     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.039     Document Type: Article

References (40)

1. Wolf P.A., D'Agostino R.B., Belanger A.J., and Kannel W.B. Probability of stroke: a risk profile from the Framingham Study. Stroke 22 (1991) 312-318
2. Dennis M.S., Burn J.P., Sandercock P.A., et al. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 24 (1993) 796-800
3. Hu G., Sarti C., Jousilahti P., et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke 36 (2005) 2538-2543
4. Menotti A., Jacobs Jr. D.R., Blackburn H., et al. Twenty-five-year prediction of stroke deaths in the seven countries study: the role of blood pressure and its changes. Stroke 27 (1996) 381-387
5. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen K., et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311 (1984) 501-505
6. Böger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38 (2006) 126-136
7. Achan V., Broadhead M., Malaki M., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 (2003) 1455-1459
8. Kielstein J.T., Salpeter S.R., Bode-Boeger S.M., Cooke J.P., and Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant 21 (2006) 2446-2451
9. Zoccali C., Bode-Böger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
10. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97 (2005) e53-59
11. Dückelmann C., Mittermayer F., Haider D.G., et al. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 27 (2007) 2037-2042
12. Krzyzanowska K., Mittermayer F., Wolzt M., and Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diab Care 30 (2007) 1834-1839
13. Maas R., Schulze F., Baumert J., et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 53 (2007) 693-701
14. Kielstein J.T., Donnerstag F., Gasper S., et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37 (2006) 2024-2029
15. Segarra G., Medina P., Ballester R.M., et al. Effects of some guanidino compounds on human cerebral arteries. Stroke 30 (1999) 2206-2210
16. Faraci F.M., Brian Jr. J.E., and Heistad D.D. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 269 (1995) H1522-1527
17. Yoo J.H., and Lee S.C. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 158 (2001) 425-430
18. Wanby P., Teerlink T., Brudin L., et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 185 (2006) 271-277
19. Kiechl S., Lee T., Santer P., et al. Symmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 205 (2009) 261-265
20. Carter A.M., Catto A.J., Mansfield M.W., Bamford J.M., and Grant P.J. Predictive variables for mortality after acute ischemic stroke. Stroke 38 (2007) 1873-1880
21. Bamford J., Sandercock P., Dennis M., Burn J., and Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337 (1991) 1521-1526
22. Monami M., Pala L., Bardini G., et al. Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) Study. Acta Diabetol 46 (2009) 191-196
23. Geddes C.C., Woo Y.M., and Brady S. Glomerular filtration rate-what is the rationale and justification of normalizing GFR for body surface area?. Nephrol Dial Transplant 23 (2008) 4-6
24. Schwedhelm E., Tan-Andresen J., Maas R., et al. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 51 (2005) 1268-1271
25. Schwedhelm E., Maas R., Tan-Andresen J., et al. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Anal Technol Biomed Life Sci 851 (2007) 211-219
26. Tsikas D., Böger R.H., Sandmann J., Bode-Böger S.M., and Frölich J.C. Hypothesis: endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 23810 (2000) 1-3
27. Böger R.H., Sydow K., Borlak J., et al. LDL Cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87 (2000) 99-105
28. Cardounel A.J., Cui H., Samouilov A., et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 282 (2007) 879-887
29. Closs E.I., Basha F.Z., Habermeier A., and Förstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1 (1997) 65-73
30. Schulze F., Lenzen H., Hanefeld C., et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 152 493 (2006) e1-8
31. Krempl T.K., Kähler J., Maas R., et al. Elevation of asymmetric dimethylarginine (ADMA) in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 26 (2005) 1846-1851
32. Leong T., Zylberstein D., Graham I., et al. Swedish-Irish-Norwegian Collaboration. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 28 (2008) 961-967
33. Zeller M., Korandji C., Guilland J.C., et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol 28 (2008) 954-960
34. Carello K.A., Whitesall S.E., Lloyd M.C., Billecke S.S., and D'Alecy L.G. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 290 (2006) H209-H216
35. MacAllister R.J., Rambausek M.H., Vallance P., et al. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11 (1996) 2449-2452
36. G-dimethylarginine in rats. Arch Biochem Biophys 252 (1987) 526-537
37. Kielstein JT, Fliser D, Veldink H. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance? Semin Dial; in press.
38. Weiner D.E., Tighiouart H., Amin M.G., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15 (2004) 1307-1315
39. Astor B.C., Hallan S.I., Miller III E.R., Yeung E., and Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 167 (2008) 1226-1234
40. Schepers E., Glorieux G., Dhondt A., Leybaert L., and Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 24 (2009) 1429-1435